A new clinical trial aimed at exploring the potential of GLP-1 medications to reduce drug and alcohol dependence has been launched with $13 million in funding. Supported by Arnold Ventures, the Center for Addiction Science, Policy and Research (CASPR), and the Allegheny County Department of Human Services, the randomized controlled study will evaluate whether weekly injections of Ozempic or Wegovy, combined with standard care, can lower alcohol and opioid use, reduce interactions with the criminal justice system, and improve employment, health, and housing outcomes among individuals at high risk of legal involvement.
GLP-1 drugs, primarily used to treat diabetes and obesity, have shown promise as a novel approach to addiction treatment due to their long-lasting effects and low potential for abuse. Unlike medications such as methadone or naltrexone, which often require daily administration or timing around substance use, GLP-1s can be administered as a once-weekly injection. This convenience may facilitate better adherence, particularly for people with chronic addictions. Additionally, early studies suggest these drugs may be effective even for addictions lacking current medication options, such as cocaine dependence. Besides addiction-related benefits, GLP-1 agonists commonly produce positive side effects including weight loss, improved blood sugar control, lower cholesterol, and reduced inflammation.
Despite widespread availability of short-term detox and rehabilitation programs—often covered by federal funding under the Affordable Care Act—long-term success in overcoming addiction remains elusive for many individuals. Experts note that addiction frequently requires substantial lifestyle changes that standard rehab programs may not fully address. Furthermore, existing harm reduction strategies that focus on providing clean needles, housing, and medical care without requiring abstinence have not sufficiently reduced rates of homelessness, unemployment, or child neglect associated with addiction.
Proponents of the trial argue that addressing cravings—a core barrier to recovery—could enhance responsiveness to behavioral interventions and social incentives such as treatment mandates linked to criminal justice or child welfare systems. Nicholas Reville, CASPR’s director, says GLP-1 medications help “quiet the noise” of cravings, giving patients more control over their decisions related to substance use.
Previous pilot programs conducted by CASPR have yielded encouraging results. One participant, Jessica Massarone, who struggled with cocaine and opioid addiction for over a decade, credited GLP-1 treatment with helping her overcome urges and regain sobriety after nearly two years. Her children, previously placed in foster care, are now part of a renewed effort to rebuild family relationships.
The forthcoming clinical trial seeks to build on these findings by rigorously assessing whether GLP-1 treatment can serve as an effective tool in reducing substance use and related social harms on a larger scale. Researchers hope that by diminishing cravings, these medications can empower individuals to engage more fully in recovery programs and restore stability in their lives.